Conflict of Interest: Jari Haukka reported research collaborations with the companies Janssen-Cilag, Eli Lilly, and Astellas. Other authors had no conflict of interest to declare.
Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma†
Article first published online: 6 MAY 2010
Copyright © 2010 UICC
International Journal of Cancer
Volume 128, Issue 6, pages 1414–1424, 15 March 2011
How to Cite
Gandini, S., Boniol, M., Haukka, J., Byrnes, G., Cox, B., Sneyd, M. J., Mullie, P. and Autier, P. (2011), Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int. J. Cancer, 128: 1414–1424. doi: 10.1002/ijc.25439
- Issue published online: 28 JAN 2011
- Article first published online: 6 MAY 2010
- Manuscript Accepted: 16 APR 2010
- Manuscript Received: 7 JAN 2010
- vitamin D;
- observational study;
Epidemiological studies have suggested a reduced risk of several cancers associated with high vitamin D status. We performed a systematic review with meta-analyses of observational studies of serum 25-hydroxyvitamin D level and colorectal, breast and prostate cancer and colonic adenoma. The literature of December 2009 was searched without language restriction. The meta-regression analysis was done to compute dose-response effects. Because in case-control studies, serum 25-hydroxyvitamin D level is measured after the diagnosis of cancer, separate analyses for case-control and prospective studies were done. We identified 35 independent studies. The seven studies on colorectal adenomas were heterogeneous in terms of endpoint and control for major confounding factors, and we did not perform a meta-analysis of these data. The summary relative risk (SRR) and (95% confidence interval) for a 10 ng/ml increase in serum 25-hydroxyvitamin D was 0.85 (0.79; 0.91) for colorectal cancer (2,630 cases in 9 studies); 0.89 (0.81;0.98) for breast cancer (6,175 cases in 10 studies); and 0.99 (0.95;1.03) for prostate cancer (3,956 cases in 11 studies). For breast cancer, case-control studies (3,030 cases) had major limitations and obtained SRR of 0.83 (0.79; 0.87) whereas SRR of prospective studies (3,145 cases) was 0.97 (0.92; 1.03). For colorectal and breast cancer, differences between cases and controls in the season of blood draw or in overweight/obesity or physical inactivity could not explain the results. In conclusion, a consistent inverse relationship between serum 25-hydroxyvitamin D levels and colorectal cancer was found. No association was found for breast and prostate cancer.